#United States #Pasadena #Heart Failure #Ventric Health #Vivio System

Ventric Health's Vivio System Revolutionizes Heart Failure Screening

In an impactful move for early heart failure (HF) detection, Ventric Health has unveiled the findings of a multicenter study showcasing the Vivio® System's effectiveness across diverse healthcare settings. Traditionally, diagnosing HF involved invasive procedures and complex imaging techniques. However, this cutting-edge system enables healthcare providers to non-invasively assess patients' left ventricular end-diastolic pressure (LVEDP), which serves as a crucial indicator of heart failure.

The newly published study in the journal Physiological Measurement presented findings from over 1,238 high-risk patients evaluated across 25 primary care sites. The key outcomes from this comprehensive screening indicated a staggering 92% diagnostic yield, revealing the versatility and accuracy of the Vivio System in real-world applications. Notably, 40% of participants demonstrated elevated levels of LVEDP, pointing to significant cardiogenic congestion.

Key Findings

1. High Diagnostic Success Rate: The study highlighted a conclusive diagnostic rate of 92.2%, showcasing the Vivio System's reliability in fast-paced outpatient environments, allowing for immediate patient assessment and intervention.
2. Substantial Detection of Elevated LVEDP: Almost 40.1% of patients screened exhibited elevated LVEDP levels greater than 18 mmHg, according to the integrated Kansas City Cardiomyopathy Questionnaire (KCCQ-12), providing objective evidence of heart dysfunction.
3. Identification of Asymptomatic HF: The integrated approach also uncovered that 42.3% of patients with elevated LVEDP were asymptomatic, emphasizing the need for proactive heart health management before serious conditions develop.
4. Demographic Equity: Importantly, the screening process did not show any selection bias related to age, gender, or body mass index (BMI), making it a universally applicable tool for patient assessment.

Transforming Heart Failure Diagnosis

The Vivio System effectively replaces invasive methods, enabling a streamlined five-minute screening to be integrated easily into existing healthcare workflows, such as annual wellness visits or standard check-ups. Dr. Thomas Cheek, the Chief Medical Officer at Ventric Health, expressed confidence in the system's role, stating, "These findings demonstrate that the Vivio-facilitated screening workflow can be seamlessly integrated into scalable, population-level care models."

Moreover, the approach empowers medical assistants to conduct the tests independently, significantly reducing the burden on physicians while enhancing disease detection capabilities. The operational feasibility of the Vivio System provides a clear path towards reshaping how primary care manages heart failure risks, transitioning from reactive to proactive healthcare strategies.

Further Evidence and Validation

This study adds to a growing body of clinical evidence regarding the Vivio system. Previously, the device had been validated through a 2026 multicenter JAHA validation study and presented results at the 2025 Heart Failure Society of America (HFSA) conference. Each subsequent piece of research reinforces the Vivio's effectiveness in various clinical settings, ensuring reliable detection rates across different workflows.

Conclusion

The Vivio System's non-invasive method radically changes the landscape of heart failure screening. By facilitating early detection, this innovative technology not only improves patient outcomes but optimizes healthcare resources across the board. With the potential to standardize heart failure screenings nationwide, Ventric Health stands poised to lead a significant transformation in cardiovascular care.

For more information regarding the Vivio System and its potential to enhance heart failure detection, visit Ventric Health.